Xenon Pharmaceuticals Inc. (XENE): Capital Expenditures
$799.0K
Year ended 2025-12-31
$1.01M
Trailing 12 months to 2026-06-30
-34.9%
3-year compound annual growth
-21.2%
5-year compound annual growth
+3.8%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $799.0K | -74.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $3.08M | -45.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $5.62M | +94.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $2.89M | +41.2% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $2.05M | -22.3% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $2.64M | +112.7% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $1.24M | +144.6% | 2021-03-01, From 2019-01-01 |
| 2018-12-31 | $507.0K | +61.0% | 2020-03-09, From 2018-01-01 |
| 2017-12-31 | $315.0K | +12.9% | 2019-03-06, From 2017-01-01 |
| 2016-12-31 | $279.0K | -49.4% | 2018-03-07, From 2016-01-01 |
| 2015-12-31 | $551.0K | -64.0% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $1.53M | +880.1% | 2017-03-08, From 2014-01-01 |
| 2013-12-31 | $156.0K | -70.3% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $526.0K | n/a | 2015-03-12, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $799.0K | -74.0% |
| Adagene Inc. (ADAG) | 2025-12-31 | $17.1K | -49.2% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $72.0K | +75.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $0 | -100.0% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $111.0K | -8.3% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
| Immunome Inc. (IMNM) | 2025-12-31 | $9.69M | +35.0% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.21M | +78.5% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $518.0K | -97.1% |
Compare XENE, ADAG, BOLT, OVID side by side · Screen every company in Pharmaceutical Preparations ↗